TY - JOUR
T1 - A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia
AU - Nørskov, Kristina Holmegaard
AU - Fridthjof, Katrine
AU - Kampmann, Peter
AU - Dünweber, Anne
AU - Andersen, Christen Lykkegaard
AU - Renaberg, Toni
AU - Schöllkopf, Claudia
AU - Ahmad, Syed Azhar
AU - Schou, Katrine
AU - Jensen, Cecilie Fremming
AU - Møller, Peter
AU - Lundholm, Birgitte Wolf
AU - Marcher, Claus
AU - Østergaard Jepsen, Lene
AU - Ørntoft, Anne Katrine
AU - Ommen, Hans Beier
AU - Andersen, Lotte
AU - Behrentzs, Anni
AU - Hasselgren, Connie Fruergaard
AU - Severinsen, Marianne
AU - Grand, Mia Klinten
AU - Jarden, Mary
AU - Møller, Tom
AU - Kjeldsen, Lars
N1 - Copyright © 2021 Elsevier Ltd. All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with hematologic malignancies. We present data from a multicenter single-arm feasibility and safety study of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia and their quality of life and psychological wellbeing. This national study included patients from six sites in Denmark who received intensive chemotherapy on programmed CADD Solis infusion pumps through a central venous catheter and were also managed as outpatients during treatment-induced pancytopenia. Data are presented from 104 patients, receiving 272 treatments with 1.096 (mean 4.57, SD 3.0) home infusion days out of 1.644 treatment days (67 %). Sixty-two of 168 (36.9 %) reinduction and consolidation treatment cycles ensuing pancytopenia phases were solely handled in the outpatient clinic. Patients reported high satisfaction with home-based treatment, which had a positive influence on their ability to be involved in their treatment and be socially and physically active. No unexpected events occurred during the intervention. Overall, patients improved in all quality of life outcomes over time. Home-based intensive chemotherapy treatment was feasible and safe in this population. ClinicalTrials.gov identifier: NCT04904211.
AB - Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with hematologic malignancies. We present data from a multicenter single-arm feasibility and safety study of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia and their quality of life and psychological wellbeing. This national study included patients from six sites in Denmark who received intensive chemotherapy on programmed CADD Solis infusion pumps through a central venous catheter and were also managed as outpatients during treatment-induced pancytopenia. Data are presented from 104 patients, receiving 272 treatments with 1.096 (mean 4.57, SD 3.0) home infusion days out of 1.644 treatment days (67 %). Sixty-two of 168 (36.9 %) reinduction and consolidation treatment cycles ensuing pancytopenia phases were solely handled in the outpatient clinic. Patients reported high satisfaction with home-based treatment, which had a positive influence on their ability to be involved in their treatment and be socially and physically active. No unexpected events occurred during the intervention. Overall, patients improved in all quality of life outcomes over time. Home-based intensive chemotherapy treatment was feasible and safe in this population. ClinicalTrials.gov identifier: NCT04904211.
U2 - 10.1016/j.leukres.2021.106756
DO - 10.1016/j.leukres.2021.106756
M3 - Journal article
C2 - 34839055
SN - 0145-2126
VL - 112
JO - Leukemia Research
JF - Leukemia Research
M1 - 106756
ER -